Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Donein25on Feb 23, 2023 6:25pm
219 Views
Post# 35302204

RE:RE:RE:RE:RE:"impressive, paradigm shifting, photodynamic therapy"

RE:RE:RE:RE:RE:"impressive, paradigm shifting, photodynamic therapy"Lets keep in mind AA criteria have changed recently. Now most all applicants must show that they have confirmatory trial in place, and in some instances even patinet enrollment. My mind keeps coming back to these new 9 sites. What is their purpose? Perhaps this senario: BTD for 25 patients at 450 in coming weeks/months; AA by end of year after submission of additional 450 data, (say an additional 20-25 patients); then use 9 additional sites to help complete total enrollment by end of 2023. Our completion of the trial with 450 day serveliance can then serve as our confirmatory obligation to satisfy full FDA approval late 2024 or early 2025.
<< Previous
Bullboard Posts
Next >>